1
|
Jayawickrama Withanage T, Krieger R, Wachtel E, Patchornik G. Efficient separation of IgG from IgM antibodies via conjugated surfactant micelles. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1226:123805. [PMID: 37354733 DOI: 10.1016/j.jchromb.2023.123805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 06/14/2023] [Accepted: 06/16/2023] [Indexed: 06/26/2023]
Abstract
Immunoglobulin-G (IgG) (∼150 kDa) antibodies confer longer term immunity against bacterial or viral infections than the heavier IgM's (∼900 kDa), which are generally detectable in blood circulation in response to more recently acquired infections. There may be, however, a time overlap, which is problematic for diagnostic purposes, in the interests of which it is essential to separate IgM's from IgG's. We describe a purification platform, functioning at pH 6.5, containing Tween-20, or Brij-O20, non-ionic detergent micelles, mixed with the sugar-rich detergent dodecyl maltoside (DDM), amino acid monomer tyrosine (Tyr), and conjugated by the amphiphilic complex [(bathophenanthroline)3: Fe2+]. Using conjugated Brij-O20 micelles, with input molar ratio IgG: IgM 9:1, IgG is recovered at 10 °C with 85-90% yield, (by SDS-PAGE densitometry) and ≥95% purity (also by SDS-PAGE), while IgM's are recovered at lower yields (28-34%) and contain small amounts of co-extracted IgG's. Addition of E. coli lysate as an artificial contamination background does not reduce the yield or purity of the recovered IgG. Tween-20/DDM/Tyr micelles lead to IgG purity ≥95% similar to that of Brij-O20, but with lower process yields (64-70%, by densitometry). Chromatographic separation with Protein A or Protein G resins leads to yields comparable to those obtained with Brij-O20 micelles, but with lower purity.
Collapse
Affiliation(s)
| | - Rami Krieger
- Department of Chemical Sciences, Ariel University, 70400 Ariel, Israel
| | - Ellen Wachtel
- Faculty of Chemistry, Weizmann Institute of Science, 76100 Rehovot, Israel
| | - Guy Patchornik
- Department of Chemical Sciences, Ariel University, 70400 Ariel, Israel.
| |
Collapse
|
2
|
Dhandapani G, Wachtel E, Patchornik G. Conjugated surfactant micelles: A non‐denaturing purification platform for concentrated human immunoglobulin G. NANO SELECT 2023. [DOI: 10.1002/nano.202200251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023] Open
|
3
|
Chen SW, Hoi KM, Mahfut FB, Yang Y, Zhang W. Effective flow-through polishing strategies for knob-into-hole bispecific antibodies. BIORESOUR BIOPROCESS 2022; 9:98. [PMID: 38647877 PMCID: PMC10992779 DOI: 10.1186/s40643-022-00590-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 09/02/2022] [Indexed: 11/10/2022] Open
Abstract
Bispecific antibodies (bsAbs), though possessing great therapeutic potential, are extremely challenging to obtain at high purity within a limited number of scalable downstream processing steps. Complementary to Protein A chromatography, polishing strategies play a critical role at removing the remaining high molecular weight (HMW) and low molecular weight (LMW) species, as well as host cell proteins (HCP) in order to achieve a final product of high purity. Here, we demonstrate using two knob-into-hole (KiH) bsAb constructs that two flow-through polishing steps utilising Capto Butyl ImpRes and Capto adhere resins, performed after an optimal Protein A affinity chromatography step can further reduce the HCP by 17- to 35-fold as well as HMW and LMW species with respect to monomer by ~ 4-6% and ~ 1%, respectively, to meet therapeutical requirement at 30-60 mg/mL-resin (R) load. This complete flow-through polishing strategy, guided by Design of Experiments (DoE), eliminates undesirable aggregation problems associated with the higher aggregation propensity of scFv containing bsAbs that may occur in the bind and elute mode, offering an improved ease of overall process operation without additional elution buffer preparation and consumption, thus aligning well with process intensification efforts. Overall, we demonstrate that through the employment of (1) Protein A chromatography step and (2) flow-through polishing steps, a final product containing < 1% HMW species, < 1% LMW species and < 100 ppm HCP can be obtained with an overall process recovery of 56-87%.
Collapse
Affiliation(s)
- Serene W Chen
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore
| | - Kong Meng Hoi
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore
| | - Farouq Bin Mahfut
- Cell Line Development Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore
| | - Yuansheng Yang
- Cell Line Development Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore
| | - Wei Zhang
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore.
| |
Collapse
|
4
|
Dhandapani G, Wachtel E, Das I, Sheves M, Patchornik G. Conjugated Detergent Micelles as a Platform for IgM Purification. Biotechnol Bioeng 2022; 119:1997-2003. [PMID: 35324016 PMCID: PMC9325453 DOI: 10.1002/bit.28089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 01/31/2022] [Accepted: 03/20/2022] [Indexed: 12/02/2022]
Abstract
Immunoglobulin M (IgM) antibodies hold promise as anticancer drugs and as agents for promoting immune homeostasis. This promise has not been realized due to low expression levels in mammalian cells producing IgM class antibodies, and the failure of protein A chromatography for IgM purification. Here, we describe a nonchromatographic platform for quantitatively capturing IgMs at neutral pH, which is then recovered with 86%–94% yield and >95% purity at pH 3. The platform contains micelles conjugated with the [(bathophenanthroline)3:Fe2+] amphiphilic complex. Inclusion of amino acid monomers, for example, phenylalanine or tyrosine, during conjugation of detergent micelles, allows subsequent extraction of IgMs at close to neutral pH. With the successful implementation of this purification platform for both polyclonal humans and bovine IgMs, we anticipate similar results for monoclonal IgMs, most relevant for the pharmaceutical industry.
Collapse
Affiliation(s)
| | - Ellen Wachtel
- Faculty of Chemistry, Weizmann Institute of Science, 76100, Rehovot, Israel
| | - Ishita Das
- Faculty of Chemistry, Weizmann Institute of Science, 76100, Rehovot, Israel
| | - Mordechai Sheves
- Faculty of Chemistry, Weizmann Institute of Science, 76100, Rehovot, Israel
| | - Guy Patchornik
- Department of Chemical Sciences, Ariel University, 70400, Ariel, Israel
| |
Collapse
|
5
|
Chen SW, Zhang W. Current trends and challenges in the downstream purification of bispecific antibodies. Antib Ther 2021; 4:73-88. [PMID: 34056544 PMCID: PMC8155696 DOI: 10.1093/abt/tbab007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 04/06/2021] [Accepted: 04/29/2021] [Indexed: 12/12/2022] Open
Abstract
Bispecific antibodies (bsAbs) represent a highly promising class of biotherapeutic modality. The downstream processing of this class of antibodies is therefore of crucial importance in ensuring that these products can be obtained with high purity and yield. Due to the various fundamental structural similarities between bsAbs and monoclonal antibodies (mAbs), many of the current bsAb downstream purification methodologies are based on the established purification processes of mAbs, where affinity, charge, size, hydrophobicity and mixed-mode-based purification are frequently employed. Nevertheless, the downstream processing of bsAbs presents a unique set of challenges due to the presence of bsAb-specific byproducts, such as mispaired products, undesired fragments and higher levels of aggregates, that are otherwise absent or present in lower levels in mAb cell culture supernatants, thus often requiring the design of additional purification strategies in order to obtain products of high purity. Here, we outline the current major purification methods of bsAbs, highlighting the corresponding solutions that have been proposed to circumvent the unique challenges presented by this class of antibodies, including differential affinity chromatography, sequential affinity chromatography and the use of salt additives and pH gradients or multistep elutions in various modes of purification. Finally, a perspective towards future process development is offered.
Collapse
Affiliation(s)
- Serene W Chen
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore 138668, Singapore
| | - Wei Zhang
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore 138668, Singapore
| |
Collapse
|
6
|
Dhandapani G, Wachtel E, Sheves M, Patchornik G. Nonionic detergent micelle aggregates: An economical alternative to protein A chromatography. N Biotechnol 2020; 61:90-98. [PMID: 33279718 DOI: 10.1016/j.nbt.2020.11.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 11/23/2020] [Accepted: 11/28/2020] [Indexed: 10/22/2022]
Abstract
We have recently described a non-chromatographic, ligand-free approach for antibody (Ab) purification based on specially designed [Tween-20:bathophenanthroline:Fe2+] aggregates. To assess the potential generality of this approach, a variety of detergents belonging to four nonionic detergent families (Tween, Brij, Triton and Pluronic) have now been studied. All surfactant aggregates led to high purity of the recovered Ab's (>95 %, by gel densitometry). Good overall Ab recovery yields were observed with Tween-20 (80-83 %), Brij-O20 (85-87 %) and Triton X-100 (87-90 %), while Pluronic F-127 was less efficient (42-53 %). Of additional importance is the finding that the process was performed by filtration rather than centrifugation, thereby allowing a continuous purification mode that led to the recovery of monomeric IgG, as determined by dynamic light scattering and preservation of Ab specificity as measured by ELISA. The amphiphilic chelator, bathophenanthroline (batho) was recycled almost quantitatively (95 %) by crystallization. Good IgG recovery yields of ∼80 % were also observed when Ab concentrations were increased from 1 mg/mL to 3-5 mg/mL. Potential advantages of the purification platform for industrial downstream processing of therapeutic monoclonal antibodies, are discussed.
Collapse
Affiliation(s)
| | - Ellen Wachtel
- Faculty of Chemistry, Weizmann Institute of Science, 76100, Rehovot, Israel
| | - Mordechai Sheves
- Faculty of Chemistry, Weizmann Institute of Science, 76100, Rehovot, Israel
| | - Guy Patchornik
- Department of Chemical Sciences, Ariel University, 70400, Ariel, Israel.
| |
Collapse
|
7
|
Evans AR, Capaldi MT, Goparaju G, Colter D, Shi FF, Aubert S, Li LC, Mo J, Lewis MJ, Hu P, Alfonso P, Mehndiratta P. Using bispecific antibodies in forced degradation studies to analyze the structure-function relationships of symmetrically and asymmetrically modified antibodies. MAbs 2019; 11:1101-1112. [PMID: 31161859 PMCID: PMC6748611 DOI: 10.1080/19420862.2019.1618675] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Forced degradation experiments of monoclonal antibodies (mAbs) aid in the identification of critical quality attributes (CQAs) by studying the impact of post-translational modifications (PTMs), such as oxidation, deamidation, glycation, and isomerization, on biological functions. Structure-function characterization of mAbs can be used to identify the PTM CQAs and develop appropriate analytical and process controls. However, the interpretation of forced degradation results can be complicated because samples may contain mixtures of asymmetrically and symmetrically modified mAbs with one or two modified chains. We present a process to selectively create symmetrically and asymmetrically modified antibodies for structure-function characterization using the bispecific DuoBody® platform. Parental molecules mAb1 and mAb2 were first stressed with peracetic acid to induce methionine oxidation. Bispecific antibodies were then prepared from a mixture of oxidized or unoxidized parental mAbs by a controlled Fab-arm exchange process. This process was used to systematically prepare four bispecific mAb products: symmetrically unoxidized, symmetrically oxidized, and both combinations of asymmetrically oxidized bispecific mAbs. Results of this study demonstrated chain-independent, 1:2 stoichiometric binding of the mAb Fc region to both FcRn receptor and to Protein A. The approach was also applied to create asymmetrically deamidated mAbs at the asparagine 330 residue. Results of this study support the proposed 1:1 stoichiometric binding relationship between the FcγRIIIa receptor and the mAb Fc. This approach should be generally applicable to study the potential impact of any modification on biological function.
Collapse
Affiliation(s)
- Adam R Evans
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Michael T Capaldi
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Geetha Goparaju
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - David Colter
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Frank F Shi
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Sarah Aubert
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Lian-Chao Li
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Jingjie Mo
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Michael J Lewis
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Ping Hu
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Pedro Alfonso
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA
| | - Promod Mehndiratta
- a Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.,b Analytical Development, Biologics Research and Development, Celgene Corporation , Summit , NJ , USA
| |
Collapse
|
8
|
Li Y. A brief introduction of IgG-like bispecific antibody purification: Methods for removing product-related impurities. Protein Expr Purif 2019; 155:112-119. [DOI: 10.1016/j.pep.2018.11.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 11/30/2018] [Indexed: 01/04/2023]
|
9
|
Dhandapani G, Howard A, Truong TV, Baiju TV, Kesselman E, Friedman N, Wachtel E, Sheves M, Danino D, Namboothiri INN, Patchornik G. A general platform for antibody purification utilizing engineered-micelles. MAbs 2019; 11:583-592. [PMID: 30618334 DOI: 10.1080/19420862.2019.1565749] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
We introduce a new concept and potentially general platform for antibody (Ab) purification that does not rely on chromatography or specific ligands (e.g., Protein A); rather, it makes use of detergent aggregates capable of efficiently capturing Ab while rejecting hydrophilic impurities. Captured Ab are then extracted from the aggregates in pure form without co-extraction of hydrophobic impurities or aggregate dissolution. The aggregates studied consist of conjugated "Engineered-micelles" built from the nonionic detergent, Tween-20; bathophenanthroline, a hydrophobic metal chelator, and Fe2+ions. When tested in serum-free media with or without bovine serum albumin as additive, human or mouse IgGs were recovered with good overall yields (70-80%, by densitometry). Extraction of IgGs with 7 different buffers at pH 3.8 sheds light on possible interactions between captured Ab and their surrounding detergent matrix that lead to purity very similar to that obtained via Protein A or Protein G resins. Extracted Ab preserve their secondary structure, specificity and monomeric character as determined by circular dichroism, enzyme-linked immunosorbent assay and dynamic light scattering, respectively.
Collapse
Affiliation(s)
| | - Assaf Howard
- a Department of Chemical Sciences , Ariel University , Ariel , Israel
| | - Thien Van Truong
- a Department of Chemical Sciences , Ariel University , Ariel , Israel
| | - Thekke V Baiju
- b Department of Chemistry , Indian Institute of Technology Bombay , Powai , India
| | - Ellina Kesselman
- c Faculty of Biotechnology and Food Engineering , Technion , Haifa , Israel
| | - Noga Friedman
- d Faculty of Chemistry , Weizmann Institute of Science , Rehovot , Israel
| | - Ellen Wachtel
- d Faculty of Chemistry , Weizmann Institute of Science , Rehovot , Israel
| | - Mordechai Sheves
- d Faculty of Chemistry , Weizmann Institute of Science , Rehovot , Israel
| | - Dganit Danino
- c Faculty of Biotechnology and Food Engineering , Technion , Haifa , Israel
| | | | - Guy Patchornik
- a Department of Chemical Sciences , Ariel University , Ariel , Israel
| |
Collapse
|
10
|
Wang L, Marcus RK. Evaluation of protein separations based on hydrophobic interaction chromatography using polyethylene terephthalate capillary-channeled polymer (C-CP) fiber phases. J Chromatogr A 2019; 1585:161-171. [DOI: 10.1016/j.chroma.2018.11.068] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Revised: 11/16/2018] [Accepted: 11/24/2018] [Indexed: 11/28/2022]
|
11
|
Andrade C, Arnold L, Motabar D, Aspelund M, Tang A, Hunter A, Chung WK. An Integrated Approach to Aggregate Control for Therapeutic Bispecific Antibodies Using an Improved Three Column Mab Platform-Like Purification Process. Biotechnol Prog 2018; 35:e2720. [PMID: 30298991 PMCID: PMC6667909 DOI: 10.1002/btpr.2720] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Revised: 09/17/2018] [Accepted: 09/17/2018] [Indexed: 12/23/2022]
Abstract
Single chain variable fragment‐IgGs (scFv‐IgG) are a class of bispecific antibodies consisting of two single chain variable fragments (scFv) that are fused to an intact IgG molecule. A common trend observed for expression of scFv‐IgGs in mammalian cell culture is a higher level of aggregates (10%–30%) compared to mAbs, which results in lower purification yields in order to meet product quality targets. Furthermore, the high aggregate levels also pose robustness risks to a conventional mAb three column platform purification process which uses only the polishing steps (e.g., cation exchange chromatography [CEX]) for aggregate removal. Protein A chromatography with pH gradient elution, high performance tangential flow filtration (HP‐TFF) and calcium phosphate precipitation were evaluated at the bench scale as means of introducing orthogonal aggregate removal capabilities into other aspects of the purification process. The two most promising process variants, namely Protein A pH gradient elution followed by calcium phosphate precipitation were evaluated at pilot scale, demonstrating comparable performance. Implementing Protein A chromatography with gradient elution and/or calcium phosphate precipitation removed a sufficient portion of the aggregate burden prior to the CEX polishing step, enabling CEX to be operated robustly under conditions favoring higher monomer yield. From starting aggregate levels ranging from 15% to 23% in the condition media, levels were reduced to between 2% and 3% at the end of the CEX step. The overall yield for the optimal process was 71%. Results of this work suggest an improved three‐column mAb platform‐like purification process for purification of high aggregate scFv‐IgG bispecific antibodies is feasible. © 2018 The Authors. Biotechnology Progress published by Wiley Periodicals, Inc. on behalf of American Institute of Chemical Engineers. Biotechnol. Prog., 35: e2720, 2019
Collapse
Affiliation(s)
- Cassia Andrade
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Lindsay Arnold
- Process Development Engineering, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Dana Motabar
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Matthew Aspelund
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Alison Tang
- Purification Process Sciences, MedImmune LLC, Cambridge, U.K
| | - Alan Hunter
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Wai Keen Chung
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| |
Collapse
|
12
|
Vasilenko EA, Mokhonov VV, Gorshkova EN, Astrakhantseva IV. Bispecific Antibodies: Formats and Areas of Application. Mol Biol 2018. [DOI: 10.1134/s0026893318020176] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
13
|
The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev 2017; 122:2-19. [PMID: 27916504 DOI: 10.1016/j.addr.2016.11.004] [Citation(s) in RCA: 185] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Revised: 11/26/2016] [Accepted: 11/28/2016] [Indexed: 12/22/2022]
Abstract
It has been over four decades since the development of monoclonal antibodies (mAbs) using a hybridoma cell line was first reported. Since then more than thirty therapeutic antibodies have been marketed, mostly as oncology, autoimmune and inflammatory therapeutics. While antibodies are very efficient, their cost-effectiveness has always been discussed owing to their high costs, accumulating to more than one billion dollars from preclinical development through to market approval. Because of this, therapeutic antibodies are inaccessible to some patients in both developed and developing countries. The growing interest in biosimilar antibodies as affordable versions of therapeutic antibodies may provide alternative treatment options as well potentially decreasing costs. As certain markets begin to capitalize on this opportunity, regulatory authorities continue to refine the requirements for demonstrating quality, efficacy and safety of biosimilar compared to originator products. In addition to biosimilars, innovations in antibody engineering are providing the opportunity to design biobetter antibodies with improved properties to maximize efficacy. Enhancing effector function, antibody drug conjugates (ADC) or targeting multiple disease pathways via multi-specific antibodies are being explored. The manufacturing process of antibodies is also moving forward with advancements relating to host cell production and purification processes. Studies into the physical and chemical degradation pathways of antibodies are contributing to the design of more stable proteins guided by computational tools. Moreover, the delivery and pharmacokinetics of antibody-based therapeutics are improving as optimized formulations are pursued through the implementation of recent innovations in the field.
Collapse
|
14
|
Flores-Ortiz LF, Campos-García VR, Perdomo-Abúndez FC, Pérez NO, Medina-Rivero E. PHYSICOCHEMICAL PROPERTIES OF RITUXIMAB. J LIQ CHROMATOGR R T 2014. [DOI: 10.1080/10826076.2013.794738] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
| | | | | | - Néstor O. Pérez
- a Unidad de Investigación y Desarrollo , Tenancingo , Estado de México , México
| | | |
Collapse
|
15
|
Bereli N, Ertürk G, Denizli A. Histidine Containing Macroporous Affinity Cryogels for Immunoglobulin G Purification. SEP SCI TECHNOL 2012. [DOI: 10.1080/01496395.2012.662258] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. MAbs 2010; 2:480-99. [PMID: 20647768 DOI: 10.4161/mabs.2.5.12645] [Citation(s) in RCA: 322] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Hundreds of therapeutic monoclonal antibodies (mAbs) are currently in development, and many companies have multiple antibodies in their pipelines. Current methodology used in recovery processes for these molecules are reviewed here. Basic unit operations such as harvest, Protein A affinity chromatography, and additional polishing steps are surveyed. Alternative processes such as flocculation, precipitation, and membrane chromatography are discussed. We also cover platform approaches to purification methods development, use of high throughput screening methods, and offer a view on future developments in purification methodology as applied to mAbs.
Collapse
Affiliation(s)
- Hui F Liu
- Oceanside Process Research & Development, Genentech, Inc., Oceanside, CA, USA.
| | | | | | | |
Collapse
|
17
|
Subramanian A, Roy S, Mascoli C, Hommerding J. Use of Modified Chitosan Macrospheres in the Selective Removal of Immunoglobulins. J LIQ CHROMATOGR R T 2009. [DOI: 10.1081/jlc-200029111] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Anuradha Subramanian
- a Department of Chemical Engineering , University of Nebraska , Lincoln , Nebraska , 68588‐0126 , USA
| | - Swapan Roy
- b LigoChem Inc. , Fairfield , New Jersey , USA
| | | | - Jennifer Hommerding
- c Biosystems and Agricultural Engineering , University of Minnesota , St. Paul , Minnesota , USA
| |
Collapse
|
18
|
Evans DRH, Macniven RP, Labanca M, Walker J, Notarnicola SM. Purification of an Fc-fusion biologic: Clearance of multiple product related impurities by hydrophobic interaction chromatography. J Chromatogr A 2008; 1177:265-71. [PMID: 17692855 DOI: 10.1016/j.chroma.2007.07.049] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2007] [Revised: 07/19/2007] [Accepted: 07/24/2007] [Indexed: 11/20/2022]
Abstract
An hydrophobic interaction chromatography step was developed for the large-scale production of an Fc-fusion biologic. Two abundant product-related impurities were separated from the active monomer using a Butyl resin and a simple step-wash and step-elution strategy. Capacity and resolution of the HIC step was optimal when sodium sulfate was employed as the lyotropic salt and pore size of the Butyl resin was 750A. Factorial analysis identified critical parameters for the Butyl chromatography and an operating window capable of delivering high product quality and yield over a broad column loading range.
Collapse
Affiliation(s)
- David R H Evans
- Biogen Idec Corporation, Bioprocess Development, 14 Cambridge Center, Cambridge, MA 02142, USA.
| | | | | | | | | |
Collapse
|
19
|
To BCS, Lenhoff AM. Hydrophobic interaction chromatography of proteins. J Chromatogr A 2007; 1141:191-205. [PMID: 17207806 DOI: 10.1016/j.chroma.2006.12.020] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2006] [Revised: 11/30/2006] [Accepted: 12/05/2006] [Indexed: 11/18/2022]
Abstract
The contributions of protein and adsorbent properties to retention and recovery were examined for hydrophobic interaction chromatography (HIC) using eight commercially available phenyl media and five model proteins (ribonuclease A, lysozyme, alpha-lactalbumin, ovalbumin and BSA). The physical properties of the adsorbents were determined by inverse size exclusion chromatography (ISEC). The adsorbents examined differ from each other in terms of base matrix, ligand density, porosity, mean pore radius, pore size distribution (PSD) and phase ratio, allowing systematic studies to understand how these properties affect protein retention and recovery in HIC media. The proteins differ in such properties as adiabatic compressibility and molecular mass. The retention factors of the proteins in the media were determined by isocratic elution. The results show a very clear trend in that proteins with high adiabatic compressibility (higher flexibility) were more strongly retained. For proteins with similar adiabatic compressibilities, those with higher molecular mass showed stronger retention in Sepharose media, but this trend was not observed in adsorbents with polymethacrylate and polystyrene divinylbenzene base matrices. This observation could be related to protein recovery, which was sensitive to protein flexibility, molecular size, and conformation as well as the ligand densities and base matrices of the adsorbents. Low protein recovery during isocratic elution could affect the interpretation of protein selectivity results in HIC media. The retention data were fitted to a previously published retention model based on the preferential interaction theory, in terms of which retention is driven by release of water molecules and ions upon protein-adsorbent interaction. The calculated number of water molecules released was found to be statistically independent of protein retention strength and adsorbent and protein properties.
Collapse
Affiliation(s)
- Brian C S To
- Merck Research Laboratories, Sumneytown Pike, West Point, PA 19486, USA
| | | |
Collapse
|
20
|
Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. J Biochem 2006; 140:359-68. [PMID: 16861252 DOI: 10.1093/jb/mvj157] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Bispecific antibodies (bsAbs) have the potential to extend binding selectivity, increase avidity and exert potent cytotoxicity due to the combination of dual specificities. scFv2-Fc type of single-gene-encoded bispecific antibody, composed of two different single-chain Fvs and an Fc, has been reported to be capable of binding to different antigens. The aim of this study was to determine the effect of fucose removal on effector functions of scFv2-Fc since fucose depletion from oligosaccharide of human IgG1 and scFv-Fc results in significant enhancement of ADCC. We generated novel single-gene-encoded bsAb with dual specificity against tumor associated glycoprotein (TAG)-72 and MUC1 mucin as fucose-negative scFv2-Fc from alpha-1,6-fucosyltransferase knock-out CHO cells and a highly fucosylated scFv2-Fc comparator from parental CHO cells. Expression, assembly and the antigen-binding activity of the scFv2-Fc were not influenced by removal of fucose. The fucose negative scFv2-Fc bound with higher avidity to FcgammaRIIIa and enhanced ADCC compared to the highly fucosylated scFv2-Fc. These results demonstrate that ADCC-enhancement by removal of fucose is effective in not only whole IgG1 and scFv-Fc, but also scFv2-Fc targeting two different antigens, and thus increases the potential of fucose-negative scFv2-Fcs as novel therapeutic candidates.
Collapse
Affiliation(s)
- Akito Natsume
- Department of Antibody Research, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd., 3-6-6 Asahi-machi, Machida, Tokyo 194-8533, Japan
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Ghosh R, Wang L. Purification of humanized monoclonal antibody by hydrophobic interaction membrane chromatography. J Chromatogr A 2006; 1107:104-9. [PMID: 16388812 DOI: 10.1016/j.chroma.2005.12.035] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2005] [Revised: 12/06/2005] [Accepted: 12/07/2005] [Indexed: 10/25/2022]
Abstract
Humanized monoclonal antibodies (mAbs) hold significant promise as biopharmaceuticals. One of the main challenges faced in the purification of mAbs is their separation from bovine serum albumin, which is the main protein present in most mammalian cell culture media. This paper discusses the purification of humanized mAb hIgG1-CD4 from CHO cell culture media by hydrophobic interaction membrane chromatography using a stack of microporous synthetic membranes. The effects of solution conditions on mAb solubility and binding on the membrane were first studied. The separation of a simulated mixture of bovine albumin and the mAb was then carried out to examine the feasibility of mAb purification. Separation experiments carried out under optimized conditions demonstrated that this membrane-based technique could be used for mAb purification from cell culture media. High purity (97%) and recovery (in excess of 97%) were obtained.
Collapse
Affiliation(s)
- Raja Ghosh
- Department of Chemical Engineering, McMaster University, 1280 Main Street West, Hamilton, Ont., Canada L8S 4L7.
| | | |
Collapse
|
22
|
Bereli N, Uzun L, Yavuz H, Elkak A, Denizli A. Antibody purification using porous metal–chelated monolithic columns. J Appl Polym Sci 2006. [DOI: 10.1002/app.23894] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
23
|
Porous poly(hydroxyethyl methacrylate) based monolith as a new adsorbent for affinity chromatography. REACT FUNCT POLYM 2005. [DOI: 10.1016/j.reactfunctpolym.2005.05.003] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
24
|
Mowry MC, Meagher M, Smith L, Marks J, Subramanian A. Production and purification of a chimeric monoclonal antibody against botulinum neurotoxin serotype A. Protein Expr Purif 2004; 37:399-408. [PMID: 15358363 DOI: 10.1016/j.pep.2004.06.022] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2004] [Revised: 06/21/2004] [Indexed: 10/26/2022]
Abstract
Production of recombinant antibodies against botulinum neurotoxin is necessary for the development of a post-exposure treatment. CHO-DG44 cells were transfected with a plasmid encoding the light and heavy chains of a chimeric monoclonal antibody (S25) against botulism neurotoxin serotype A. Stable cell lines were obtained by dilution cloning and clones were shown to produce nearly equivalent levels of light and heavy chain antibody by an enzyme-linked immunosorbent assay (ELISA). In suspension culture, cells produced 35 microg/ml of chimeric antibody after 6 days, corresponding to a specific antibody productivity of 3.1 pg/cell/day. A method for the harvest and recovery of an antibody against botulism neurotoxin serotype A was investigated utilizing ethylenediamine-N,N'-tetra(methylphosphonic) acid (EDTPA) modified zirconia and MEP-hypercel, a hydrophobic charge interaction chromatography resin. Purification of the S25 antibody was compared to that achieved using rProtein A-Sepharose Fast Flow resin. After the direct load of culture supernatant, analysis by ELISA and gel electrophoresis showed that S25 antibody could be recovered at purities of 41 and 44%, from the EDTPA modified zirconia and MEP-hypercel columns, respectively. Although the purity obtained from each of these columns was low, the ability to withstand high column pressures and nearly 90% recovery of the antibody makes EDTPA modified zirconia well suited as an initial capture step. Combining the EDTPA modified zirconia and HCIC columns in series resulted in both purity and final product yield of 72%.
Collapse
Affiliation(s)
- Mark C Mowry
- Department of Chemical Engineering, University of Nebraska, 207 Othmer Hall, 820 North 16th Street, Lincoln, NE 68588, USA.
| | | | | | | | | |
Collapse
|
25
|
|
26
|
Jensen M, Ernestus K, Kemshead J, Klehr M, Von Bergwelt-Baildon MS, Schinköthe T, Schultze JL, Berthold F. The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. Clin Exp Immunol 2003; 134:253-63. [PMID: 14616785 PMCID: PMC1808859 DOI: 10.1046/j.1365-2249.2003.02300.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
To target the neural cell adhesion molecule (NCAM, CD56) on neuroblastoma by T cell-based immunotherapy we have generated a bi-specific CD3 x NCAM antibody (OE-1). This antibody can be used to redirect T cells to NCAM+ cells. Expectedly, the antibody binds specifically to NCAM+ neuroblastoma cells and CD3+ T cells. OE-1 induces T cell activation, expansion and effector function in peripheral blood mononuclear cell (PBMC)-derived CD4+ and CD8+ T cells. T cell activation was shown to depend on the presence of normal natural killer (NK) cells in the culture. Interestingly, while PBMC- derived T cells were activated by OE-1, NK cells were almost completely depleted, suggesting that T cells activated by OE-1 deleted the NK cells. Activated CD4+ and CD8+ T cells differentiate into a larger CCR7+ central memory and a smaller CCR7- effector memory cell population. Most importantly, preactivated T cells were highly cytotoxic for neuroblastoma cells. In eight of 11 experiments tumour-directed cytotoxicity was enhanced when NK cells were present during preactivation with OE-1. These data strongly support a bi-phasic therapeutic concept of primarily stimulating T cells with the bi-specific antibody in the presence of normal NCAM+ cells to induce T cell activation, migratory capacity and finally tumour cell lysis.
Collapse
Affiliation(s)
- M Jensen
- Department of Pediatric Oncology and Hematology, University of Cologne, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Willems A, Leoen J, Schoonooghe S, Grooten J, Mertens N. Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 786:161-76. [PMID: 12651012 DOI: 10.1016/s1570-0232(02)00813-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Antibody fragments offer the possibility to build multifunctional manifolds tailored to meet a large variety of needs. We optimized the production of a manifold consisting of one (bibody) or two (tribody) single-chain variable fragments coupled to the C-terminus of Fab chains. Different strong mammalian promoters were compared and the influence of expression media on production and recovery was investigated. Since the physical and chemical nature of these molecules largely depends on the nature of the antibody building blocks incorporated, a generally applicable process for the purification of recombinant antibody derivatives from serum containing mammalian cell culture medium was designed. To this end we compared protein L, hydroxyapatite, immobilized metal affinity chromatography, cation-exchange chromatography and hydrophobic charge induction chromatography.
Collapse
Affiliation(s)
- An Willems
- Department of Molecular Biomedical Research, Flanders Interuniversity Institute for Biotechnology (VIB), University of Ghent, K.L. Ledeganckstraat 35, 9000, Ghent, Belgium
| | | | | | | | | |
Collapse
|
28
|
Abstract
The biotechnology industry today employs recombinant bacteria, mammalian cells, and transgenic animals for the production of high-value therapeutic proteins. This article reviews the techniques employed in this industry for the recovery of these products. The methods reviewed extend from the centrifugation and membrane filtration for the initial clarification of crude culture media to the final purification of the products by a variety of membrane-based and chromatographic methods. The subject of process validation including validation of the removal of bacterial and viral contaminants from the final products is also discussed with special reference to the latest regulatory guidelines.
Collapse
|
29
|
Abstract
Hydrophobic charge induction chromatography using 4-mercapto-ethyl-pyridine as the ligand is an effective method for the separation of antibodies from a variety of feedstocks. Antibodies are adsorbed in physiological conditions without preliminary concentration. Desorption occurs when the pH is lowered, thus inducing an ionic charge of the same sign to the ligand and the antibody. Antibody capture conditions are compatible with crude samples in terms of pH, conductivity, binding capacity and expression level. The final purity of the antibody is feedstock dependent, but can reach levels of purity as high as 98%. Examples of antibody separation are given and ligand structure information discussed.
Collapse
Affiliation(s)
- Egisto Boschetti
- BioSepra, Process division of Ciphergen Biosystems, 48 Avenue des Genottes, F-95800 Cergy Pontoise, France.
| |
Collapse
|
30
|
Gupta S, Suresh M. Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates. JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS 2002; 51:203-16. [PMID: 12088881 DOI: 10.1016/s0165-022x(01)00231-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Bispecific monoclonal antibodies (bsMAb) are unique macromolecules functioning as cross-linkers with two different predetermined binding specificities. A wide range of potential applications employing these probes can be envisioned in immunodiagnostics and immunotherapy. One of the major limitations for the use of bsMAbs produced by hybrid-hybridomas is the production of parental monospecific antibodies along with bsMAbs. Hence, the purification of desired bsMAb free from both parental mAbs and other possible promiscuous combinations is essential. Purification of antibodies is the single greatest obstacle in obtaining an immunoprobe with high specific activity. This review describes the affinity purification and affinity co-purification techniques for the separation of bsMAb as a pre-formed immune complex or as a pure species. The use of immobilized ligands is the basis of affinity chromatography. Affinity chromatography can be classified into three different categories depending on the properties of the immobilized ligand. The ligand-specific affinity chromatography is based on the extremely specific immobilized ligand, directed towards the protein or antibody of interest. Using a dual, sequential affinity chromatography, bsMAb can be purified from a mixture of bispecific and monospecific monoclonal antibodies with a ligand specific for each antibody. Thiophilic adsorption is a group-specific affinity method that can be successfully used to separate monospecific forms from bispecific species by salt gradient elution. Affinity co-chromatography offers a convenient one-step method for purification of bulk amounts of immunoconjugates for diagnostic applications by exploiting several dye-ligands known to bind certain enzymes. The same method could be potentially used for quality control and quality assurance purposes in industrial biotechnology.
Collapse
Affiliation(s)
- Seema Gupta
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada T6G 2N8
| | | |
Collapse
|
31
|
Kasche V. Physico-chemical boundaries in the continuous and one-step discontinuous affinity-chromatographic isolation of proteins. JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS 2001; 49:49-62. [PMID: 11694272 DOI: 10.1016/s0165-022x(01)00188-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
From a physico-chemical point of view, affinity chromatography has no unambiguous definition. It is generally understood as the one-step chromatographic isolation of a protein from a biological sample. For such processes the protein recovery and the adsorption capacity for a given adsorption time is limited by static and dynamic physico-chemical properties of the system. The protein recovery is limited by the ratio of the static capacity, n(s), and the dissociation constant, K, for the interaction with the immobilized binding site. The limits of these quantities for 90% and 99% protein recovery were estimated. The residence time required to reach 90% of the adsorptive capacity of an adsorbent is a function of the above static properties, the pore-diffusion coefficient, D(p), and the diffusion distance in the adsorbent. It was estimated and was found to correlate well with experimental data. The one-step discontinuous or continuous chromatographic isolation of one protein from a biological sample by means of adsorbents that separate with respect to different properties is reviewed. This is only possible with selective specific adsorbents and, in special cases, also with bifunctional adsorbents that use hydrophobic interactions for the adsorption, and electrostatic repulsion for the desorption.
Collapse
Affiliation(s)
- V Kasche
- AB Biotechnologie II, Technical University Hamburg-Harburg, Denickestrasse 15, D-21071 Hamburg, Germany.
| |
Collapse
|
32
|
Boschetti E. The use of thiophilic chromatography for antibody purification: a review. JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS 2001; 49:361-89. [PMID: 11694289 DOI: 10.1016/s0165-022x(01)00208-1] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- E Boschetti
- Biosepra-Life Technologies Division of Invitrogen, 48, Avenue des Genottes, 95800 Cergy Saint Christophe, France.
| |
Collapse
|
33
|
Guerrier L, Flayeux I, Boschetti E. A dual-mode approach to the selective separation of antibodies and their fragments. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 2001; 755:37-46. [PMID: 11393728 DOI: 10.1016/s0378-4347(00)00598-3] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A novel chromatography method for the separation of antibodies is described. The adsorption of antibodies on the solid phase involves interaction with a ligand that combines mild hydrophobic characteristics and some degree of molecular recognition with a derivative of pyridine. This combined effect results in the adsorption of antibodies in the absence of lyotropic salts. When environmental pH is changed, the ligand becomes ionically charged, allowing the desorption of antibodies. The mechanism of adsorption, involving hydrophobic associations and ionic related interaction, is here qualified as dual-mode. Studies on the determination of the apparent dissociation constant for immunoglobulins G are presented. Adsorption of antibodies from crude feedstocks typically occurs without adjustment of pH or ionic strength. The sorbent is then washed with a buffer to eliminate protein impurities and, when lowering the environmental pH, antibodies are desorbed. The solid-phase material is used for the separation of antibodies from an ascites fluid and from a cell culture supernatant, followed by a polishing step on an hydroxyapatite column. Preliminary studies, related to the ability of the solid phase to separate antibody fragments, are also reported. In these studies, it has been demonstrated that both Fab and Fc fragments from polyclonal IgG are adsorbed to the solid phase under typical binding conditions. Under other defined physico-chemical conditions (ionic strength and pH), separation of both fragments in a single step has been achieved.
Collapse
Affiliation(s)
- L Guerrier
- Biosepra S.A., Life Technologies, Cergy-Pontoise, France.
| | | | | |
Collapse
|
34
|
Abstract
Antibodies tagged with enzymes, e.g. horseradish peroxidase (HRPO) are used extensively in a broad range of immunoassay, immunohistochemical, and prodrug-based immunotherapeutic applications. These antibodies may be polyclonal, monoclonal, bispecific or genetically engineered in origin. Often, purification of the antibody is the single greatest obstacle to obtaining immunoprobes with high specific activity [Milstein and Cuello, Nature 305 (1983) 537]. We have circumvented this problem by utilising benzhydroxamic acid-agarose to purify the antibodies tagged with HRPO as a preformed immune complex. Benzhydroxamic acid has been shown to have affinity for the active site of HRPO [de Ropp et al., Biochemistry 38 (1999) 1077]. A preliminary ammonium sulfate precipitation of 250 ml of bispecific antibody supernatant was performed and the pellet resuspended and dialysed against phosphate buffer (pH 7.0). This fraction was incubated with HRPO, then loaded on the affinity column which was washed, and the labelled bispecfic monoclonal antibodies were eluted under mild conditions (borate buffer pH 9.0). The effective yield of this bispecific antibody-HRPO complex was 30 assay plates or 3000 wells. We have also successfully co-purified covalent polyclonal-HRPO conjugates and HRPO-labelled streptavidin using a similar strategy to obtain enzyme-labelled probes with high specific activities for a multitude of applications.
Collapse
Affiliation(s)
- D R Husereau
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, T6G 2N8, Edmonton, Alberta, Canada
| | | |
Collapse
|
35
|
Manzke O, Tesch H, Borchmann P, Wolf J, Lackner K, Gossmann A, Diehl V, Bohlen H. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation. Int J Cancer 2001; 91:508-15. [PMID: 11251974 DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1068>3.0.co;2-d] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We describe the first clinical application of T-cell-recruiting bispecific antibodies directly into the tumor without the need to preactivate the effector cells. In a Phase I clinical trial, 10 patients with low-grade B-cell lymphoma were treated by a single locoregional injection of CD3xCD19 bispecific antibodies. Costimulatory signaling, which is required for the optimal activation of resting T cells, was provided by the simultaneous administration of CD28 antibodies. Equal amounts of both antibodies were injected together at 4 different dose levels (30 microg: 3 patients; 270 microg: 3 patients; 810 microg: 3 patients; 1,600 microg: 1 patient). The injection was well tolerated with mild to moderate adverse effects (2/10 patients) consisting of erythema and fever at the third dose level. The maximum tolerated dose was not reached at 810 microg of injected antibodies. Three patients showed a serum peak of TNFalpha on day 2 or 3 after the antibody application, reflecting rather an activation of CD4-positive T cells than an FcR-mediated effect. Five patients developed anti-mouse antibodies after injection of the murine immunoglobulins. Nine patients were evaluable for restaging examinations 6 weeks after the antibody application, with 2 of them (22%) showing a local clinical response. We found that a single locoregional injection of CD3xCD19+CD28 antibodies is feasible up to a dose of at least 1,600 microg of each antibody. However, the development of human anti-mouse antibodies points toward the requirement for new formats of bispecific proteins with reduced immunogenicity.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Animals
- Antibodies, Bispecific/administration & dosage
- Antibodies, Bispecific/therapeutic use
- Antigens, CD19/therapeutic use
- CD28 Antigens/therapeutic use
- CD3 Complex/therapeutic use
- CD4-Positive T-Lymphocytes/metabolism
- Cytokines/biosynthesis
- Dose-Response Relationship, Drug
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Immunoglobulins/metabolism
- Immunotherapy
- Leukemia, B-Cell/therapy
- Lymph Nodes/metabolism
- Lymphocyte Activation
- Lymphoma, B-Cell/therapy
- Lymphoma, Follicular/therapy
- Lymphoma, Mantle-Cell/therapy
- Male
- Mice
- Middle Aged
- Models, Biological
- T-Lymphocytes/immunology
- T-Lymphocytes/metabolism
- Time Factors
- Tomography, X-Ray Computed
- Tumor Necrosis Factor-alpha/metabolism
Collapse
Affiliation(s)
- O Manzke
- University of Cologne, Department of Internal Medicine I, Joseph-Stelzmann-Str.9, D-50925 Cologne, Germany
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000; 59:753-67. [PMID: 10804033 DOI: 10.2165/00003495-200059040-00003] [Citation(s) in RCA: 136] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Abnormal cell signal transduction arising from protein tyrosine kinases has been implicated in the initiation and progression of a variety of human cancers. Over the past 2 decades pharmaceutical and university laboratories have been involved in a tremendous effort to develop compounds that can selectively modulate these abnormal signalling pathways. Targeting receptor tyrosine kinases, especially the epidermal growth factor receptor subfamily, has been at the forefront of this effort as a result of strong clinical data correlating over-expression of these receptors with more aggressive cancers. There are a variety of strategies under development for inhibiting the kinase activity of these receptors, targeting both the extracellular and intracellular domains. Antibody-based approaches, immunotoxins and ligand-binding cytotoxic agents use the extracellular domain for targeted tumour therapy. Small molecule inhibitors target the intracellular catalytic region by interfering with ATP binding, while nonphosphorylatable peptides are aimed at the intracellular substrate binding region. Compounds that inhibit subsequent downstream signals from the receptor by interrupting intracellular protein recognition sequences are also being investigated. In the past 5 years enormous progress has been made in developing tyrosine kinase inhibitor compounds with sufficient potency, bioavailability and selectivity against this subfamily of receptor tyrosine kinases. The anti-HER2 monoclonal antibody, trastuzumab, for patients with metastatic breast cancer is the first of these inhibitor compounds to gain FDA approval. However, preclinical and clinical trials are ongoing with a variety of other monoclonal antibodies, immunotoxins, and small molecule quinazoline and pyrimidine-based inhibitors. Although their cytotoxic and cytostatic potential has been proven, they are not likely to replace standard chemotherapy regimens as single-agent, first-line therapeutics. Instead, their promising additive and synergistic antitumour effects in combination with standard chemotherapeutics suggest that these novel agents will find their greatest utility and efficacy in conjunction with existing anticancer agents.
Collapse
Affiliation(s)
- S B Noonberg
- University of California, San Francisco, Division of Hematology-Oncology, 94143, USA
| | | |
Collapse
|
37
|
Boschetti E, Jungbauer A. 15 Separation of antibodies by liquid chromatography. HANDBOOK OF BIOSEPARATIONS 2000. [DOI: 10.1016/s0149-6395(00)80062-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
38
|
Manzke O, Berthold F, Huebel K, Tesch H, Diehl V, Bohlen H. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow. Int J Cancer 1999; 80:715-22. [PMID: 10048973 DOI: 10.1002/(sici)1097-0215(19990301)80:5<715::aid-ijc15>3.0.co;2-p] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Bispecific CD3xCD19 antibodies and CD28 co-stimulating antibodies were used to activate T cells in bone marrow aspirates (n = 8) of children with B cell-derived acute lymphoblastic leukemia. Bone marrow specimens were incubated for 10 days with CD3xCD19 bispecific and CD28 antibodies. Changes in the numbers of T lymphocytes and tumoral B cells as well as surface expression of T cell-activation markers were determined by flow cytometry, and cytokines (human IFN-gamma, IL-2, IL-4 and IL-12) were measured in the cell culture supernatant. In 7 of 8 bone marrow samples, an increase in the number of CD4- and CD8-positive T lymphocytes was found, which correlated with an up-regulation of T cell-activation markers. Additionally, we demonstrated a decrease of tumoral B cells in 3 samples and enhanced cytotoxic T-cell activity against autologous malignant B cells. ELISpot analyses in an autologous Epstein-Barr virus model showed that bispecific antibodies (CD3xCD19+CD28) were more potent at generating T-cell responses against autologous and allogeneic tumoral targets than a combination of monospecific antibodies (CD3+CD28). Thus, T-cell targeting by CD3xCD19 bispecific and CD28 antibodies may be used to eliminate leukemic B cells ex vivo and reconstitute immunological control of residual malignant disease by the induction of anti-tumoral T-cell responses.
Collapse
Affiliation(s)
- O Manzke
- Clinic I for Internal Medicine, University of Cologne, Germany
| | | | | | | | | | | |
Collapse
|
39
|
Necina R, Amatschek K, Jungbauer A. Capture of human monoclonal antibodies from cell culture supernatant by ion exchange media exhibiting high charge density. Biotechnol Bioeng 1998. [DOI: 10.1002/(sici)1097-0290(19981220)60:6<689::aid-bit6>3.0.co;2-m] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|